Last updated 2026-09-04
- Went public
- Acquired Colospan, Jun 2026
- Raised $31.9M Follow-on PO, May 2020
Total raised
$249.8M
Last: Public Offering Jul 2023
Stage
Public
Founded
2000
Headcount
6
HQ
Ramat Gan, Israel
Sector
Biotechnology
About
Galmed Pharmaceuticals Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing therapeutics for liver, metabolic, and inflammatory diseases. Their lead compound, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule. Initially developed for Non-Alcoholic Steato-Hepatitis (NASH) and liver fibrosis, Galmed has expanded its focus to include cardiometabolic diseases and gastrointestinal oncological indications. The company is also developing Amilo-5MER, a 5 amino acid synthetic peptide. Galmed became a public company in 2014 and is traded on NASDAQ under the ticker symbol GLMD.
Funding history · 11 rounds · $249.8M total
16 events/rounds · $249.8M Total Funding: $249.8M in Public Equity
Oct 2024
Follow-on PO
$20.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2023
Follow-on PO
$7.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jul 2022
Follow-on PO
$8.7M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2021
Follow-on PO
$9.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2020
Follow-on PO
$31.9M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2018
Follow-on PO
$75.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Apr 2018
Follow-on PO
$6.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Dec 2017
Follow-on PO
$35.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Aug 2017
Follow-on PO
$2.4M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Jun 2016
Follow-on PO
$16.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2014
Follow-on PO
$38.3M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Acquisitions · 1
Jun 2026
Colospan
Undisclosed
Headcount over time
6 employees (2026-09) · 1 point
Offices
Ramat Gan, Israel · HQ / main office
Q&A
- What is Galmed Pharmaceuticals' primary focus?
- Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases.
- What is Galmed Pharmaceuticals' lead drug candidate?
- Galmed Pharmaceuticals' lead compound is Aramchol, a drug candidate for the treatment of NASH and fibrosis, currently in a Phase 3 registrational study.
- When did Galmed Pharmaceuticals go public?
- Galmed Pharmaceuticals went public on NASDAQ in March 2014.
- What was Galmed Pharmaceuticals' most recent public offering?
- In July 2023, Galmed Pharmaceuticals announced the pricing of a $7 million public offering.
- What is Galmed Pharmaceuticals' collaboration with the Hebrew University?
- Galmed Pharmaceuticals is collaborating with the Hebrew University on the development of Amilo-5MER, a 5 amino acid synthetic peptide, and recently initiated a first-in-human study for it.
- Has Galmed Pharmaceuticals been granted any recent patents?
- Yes, in February 2023, Galmed Pharmaceuticals announced the issuance of a new composition of matter patent for Aramchol meglumine salt.
- What is the employee count for Galmed Pharmaceuticals?
- Galmed Pharmaceuticals has 1-10 employees.
- Who is the current President & CEO of Galmed Pharmaceuticals?
- Allen Baharaff is the President & CEO of Galmed Pharmaceuticals.
Team · 17
Allen Baharaff
Founder · Co-Founder & Chief Executive Officer
Tuvia Gilat
Founder · Co-Founder
Doron Cohen
Chief Financial Officer
Yossi Gilgun-Sherki, Ph.D.
Executive Clinical Consultant
Tali Gorfine, M.D.
Executive Clinical Development Consultant
Liat Hayardeny - Brueck, Ph.D.
Chief Scientific Officer
Shaul E. Kadosh
Biostatistical & Clinical Research Consulting
Joseph Kaspi, Ph.D.
Senior CMC Director
Dalia Medini, Ph.D.
Analytical Advisor
Guy Nehemya, Adv.
Chief Operating Officer
John Posner
Clinical Pharmacology Specialist
Doron Shinar, Ph.D.
NCS Specialist
Yohai Stenzler, CPA
Chief Accounting Officer
David Sidransky, M.D.
Lead Independent Director
Carol L. Brosgart, M.D.
Director
Shmuel Nir
Director
Amir Poshinski
Director
Highlights
1 Patents
Tags
metabolic-diseasedrug-discoverypharmaceuticalsmicrobiomebiopharmaceuticaloral-drugscrohn-s-diseasediabetespharma-companiesinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | Galmed Pharmaceuticals Ltd. |
|---|---|
| Founded | 2000 |
| Employees (exact) | 6 |
| Market cap | $4.1M |
| Status reason | Public on NASDAQ on Mar, 2014 |
| Wikidata QID | Q19904023 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Colospan | 2026-06 |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Jul 2023 | ||||
| Feb 2021 | ||||
| Jun 2018 | ||||
| Jan 2018 | ||||
| Mar 2014 |
Radar intelligence
Web history (Wayback)
| Domain | galmedpharma.com |
|---|
Wikidata
| QID | Q19904023 |
|---|
Certificate / subdomain footprint
| Subdomains | 5 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514953512 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2013-07-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — violation (1), annual_report (4) |
| Registered address | דרך אבא הלל 16 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2026-05-26 | עדכון הפרה |
| 2026-06-24 | דו~ח שנתי-עדכון כתובת |
| 2026-06-24 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2026-06-24 | דו~ח שנתי-עדכון תחום עיסוק |
| 2026-06-24 | דו~ח שנתי-עדכון מען דיגיטלי |